EUVIMEDEUVIMED entdecken
Crossref

Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia

Anran Fan, Meiling Dong, Nanying Fan, Qingyuan Luo, Jun Mo, Lili Ai, Yanhua Zhou, Peng Zhang

Biochemical Pharmacology · 2026-09 · 251 · 118064

DOI: 10.1016/j.bcp.2026.118064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Anran Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Functional Nucleic Acids-Based Biopharmaceutical Research, Guizhou Biomanufac…. Hauptthemen laut MEDLINE: Cytarabine, Drug Resistance, Neoplasm, Cytidine Deaminase, Antimetabolites, Antineoplastic. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Education of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloid leukemia (ML) remains a therapeutic challenge due to the frequent development of resistance to frontline cytosine arabinoside (AraC). One of a key driver of this resistance is the overexpression of cytidine deaminase (CDA), which inactivates AraC. Here, we present a counterintuitive therapeutic strategy that exploits this very resistance pathway to overcome chemoresistance. We demonstrate that the 5-formyl-2'-deoxycytidine (5fdC) is activated by CDA into the cytotoxic metabolite 5-formyl-2'-deoxyuridine (5fdU) in AraC resistant leukemia cells. This CDA mediated metabolism, which undermines AraC therapy, becomes a critical vulnerability for resistant cells. In both in vitro AraC resistant cell lines and CDA overexpressing animal models, the conversion of 5fdC to 5fdU potently induces DNA damage and triggers apoptosis. Consequently, 5fdC exhibits enhanced and selective cytotoxicity specifically against AraC resistant leukemia cells, while showing comparatively less effect on sensitive cells. Our work unveils a novel metabolic targeting approach, turning a key resistance mechanism into a therapeutic Achilles' heel for treating refractory myeloid leukemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytarabineDrug Resistance, NeoplasmCytidine DeaminaseAntimetabolites, AntineoplasticLeukemia, MyeloidDeoxycytidineHumansAnimalsCell Line, TumorMice

Stichwörter der Autor:innen

5-formyl-2′-deoxycytidineAraCCDAMyeloid leukemiaResistance

Substanzen

CytarabineCytidine DeaminaseAntimetabolites, AntineoplasticDeoxycytidine

Autor:innen und Institutionen

  • Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Functional Nucleic Acids-Based Biopharmaceutical Research, Guizhou Biomanufacturing Laboratory, Guizhou Medical University, Guiyang, China; Key Lab…

Förderung

  • National Natural Science Foundation of China
  • Department of Education of Guizhou Province

Zitieren

APA

Fan, A., Dong, M., Fan, N., Luo, Q., Mo, J., Ai, L., Zhou, Y., & Zhang, P. (2026). Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia. Biochemical Pharmacology, 251, 118064. https://doi.org/10.1016/j.bcp.2026.118064

Vancouver

Fan A, Dong M, Fan N, Luo Q, Mo J, Ai L, et al. Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia. Biochemical Pharmacology. 2026;251:118064. doi:10.1016/j.bcp.2026.118064

BibTeX
@article{Fan2026,
  author = {Fan, Anran and Dong, Meiling and Fan, Nanying and Luo, Qingyuan and Mo, Jun and Ai, Lili and Zhou, Yanhua and Zhang, Peng},
  title = {Exploiting CDA-Mediated metabolism of 5fdC to overcome cytarabine resistance in Malignant myeloid cells leukemia},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {251},
  pages = {118064},
  doi = {10.1016/j.bcp.2026.118064}
}
Kostenlos starten →